Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives $6.88 Average Price Target from Analysts

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $6.8750.

Several brokerages have issued reports on SRTS. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a report on Friday, July 17th. Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Finally, Wall Street Zen downgraded shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th.

Institutional Investors Weigh In On Sensus Healthcare

Several large investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in Sensus Healthcare in the 4th quarter valued at approximately $77,000. Jane Street Group LLC acquired a new position in Sensus Healthcare during the fourth quarter worth $79,000. Ingalls & Snyder LLC acquired a new position in Sensus Healthcare during the fourth quarter worth approximately $219,000. State Street Corp lifted its position in shares of Sensus Healthcare by 5.2% in the fourth quarter. State Street Corp now owns 69,252 shares of the company’s stock valued at $276,000 after buying an additional 3,400 shares during the last quarter. Finally, North Star Investment Management Corp. acquired a new stake in shares of Sensus Healthcare in the first quarter valued at approximately $500,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Stock Down 1.0%

SRTS opened at $2.94 on Thursday. Sensus Healthcare has a 12-month low of $2.66 and a 12-month high of $5.50. The firm has a market capitalization of $48.40 million, a P/E ratio of -6.26 and a beta of 1.10. The stock’s 50 day moving average price is $2.93 and its two-hundred day moving average price is $3.74.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The business had revenue of $3.39 million during the quarter, compared to the consensus estimate of $5.32 million. Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.